Prostaglandin E₁-Induced Hyperostosis: Clinicopathologic Correlations and Possible Pathogenetic Mechanisms

References

• Luken J A. Prostaglandin therapy of congenital heart disease. Neonatal Therapeutics, T F Yeh. Mosby Year Book, St Louis 1991; 144–45
   Google Scholar
• Peled N, Dagan O, Babyn P, et al. Gastric-outlet obstruction induced by prostaglandin therapy in neonates. N Engl J Med 1992; 327: 505–10
   PubMed Web of Science ®Google Scholar
• Ueda K, Saito A, Nakano H, et al. Cortical hyperostosis following long-term administration of prostaglandin E1 in infants with cyanotic congenital heart disease. J Pediatr 1980; 97: 834–6
   PubMed Web of Science ®Google Scholar
• Sone K, Tahiro M, Fujinaga T, Tomomasa T, Tokuyama K, Kuroume T. Long-term low-term prostaglandin E1 administration. (Letter) J Pediatr 1980; 97: 866–7
   PubMed Web of Science ®Google Scholar
• Ringel R E, Haney P J, Brenner J I, et al. Periosteal changes secondary to prostaglandin administration. J Pediatr 1983; 103: 251–3
   PubMed Web of Science ®Google Scholar
• Drvaric D M, Parks W J, Wyly J B, Dooley K J, Plauth W H, Schmitt E W. Prostaglandin-induced hyperostosis. Clin Orthop 1989; 246: 300–4
   PubMedGoogle Scholar
• Woo K, Emery J, Peabody J. Cortical hyperostosis: A complication of prolonged prostaglandin infusion in infants awaiting cardiac transplantation. Pediatrics 1994; 9: 417–20
   Google Scholar
• Jørgensen H RI, Svanholm H, Høst A. Bone formation induced in an infant by systemic prostaglandin-E2 administration. Acta Orthop Scand 1988; 59: 464–6
   PubMed Web of Science ®Google Scholar
• Dietrich J W, Raisz L G. Prostaglandin in calcium and bone metabolism. Clin Orthop 1975; 111: 228–37
   Google Scholar
• Jee W S, Ueno K, Deng Y P, Woodbury D M. The effects of prostaglandin E2 in growing rats: Increased metaphyseal hard tissue and cortico-endosteal bone formation. Calcif Tissue Int 1985; 37: 148–57
   PubMed Web of Science ®Google Scholar
• Koshihara Y, Kawamura M. Prostaglandin Es stimulates calcification of human osteoblastic cells. Biochem Biophys Res Commun 1989; 159: 1206–12
   PubMed Web of Science ®Google Scholar
• Poznanski A K, Fernbach S K, Berry T E. Bone changes from prostaglandin therapy. Skeletal Radiol 1985; 14: 20–5
   PubMed Web of Science ®Google Scholar
• Eversole S L, Holman G H, Robinson R A. Hitherto undescribed characteristics of the pathology of infantile cortical hyperostosis (Caffey's disease). Bull Johns Hopkins Hosp 1957; 101: 80–99
   PubMedGoogle Scholar
• Teitelbaum S L. Metabolic and other nontumorous disorders of bone. Anderson's Pathology, 8th ed. C.V. Mosby, St Louis 1985; Vol. 2: 1742–4
   Google Scholar
• Makley J T, Dunn M J. Prostaglandin synthesis by osteoid osteoma. (Letter) Lancet 1982; 2: 42
   PubMed Web of Science ®Google Scholar
• Jee W S, Ueno K, Kimniel D B, Woodbury D M, Price P, Woodbury L A. The role of bone cells in increasing metaphyseal hard tissue in rapidly growing rats treated with prostaglandin E2. Bone 1986; 8: 171–8
   Web of Science ®Google Scholar
• Raisz L G, Martin T J. Prostaglandins in bone and mineral metabolism. Bone and Mineral Research, Annual 2, W A Peck. Elsevier, Amsterdam 1984; 286–310
   Google Scholar
• Dekel S, Francis M JO. Rabbit tibial Staphylococcus aureus osteomyelitis: Prevention of bone destruction and tibial prostaglandin formation by in vivo sodium salicylate treatment. J Bone Joint Surg [Br] 1981; 63: 178–84
   PubMedGoogle Scholar
• Dekel S, Francis M JO. Cortical hyperostosis after administration of prostaglandin E. (Letter) J Pediatr 1981; 99: 500–1
   PubMed Web of Science ®Google Scholar
• Lund J E, Brown W P, Tregerman L. The toxicology of PGE1 and PGE2. Prostaglandins in Clinical Medicine: Cardiovascular and Thrombotic Disorders, K K Wu, E C Rossi. Yearbook Medical Publishers, New York 1982; 93–109
   Google Scholar
• Lauritzen D B, Balena R, Shea M, et al. Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biochemical properties of bone in ovariectomized rats. J Bone Miner Res 1993; 8: 871–79
   PubMed Web of Science ®Google Scholar
• Kowalski J, Kwan H H, Prionas S D, Allison A C, Fajardo L F. Characterization and applications of the disc angiogenesis system. Exp Mol Pathol 1992; 56: 1–19
   PubMed Web of Science ®Google Scholar
• Nelson M J, Conley F K, Fajardo L F. Application of the disc angiogenesis system to tumor-induced neovascularization. Exp Mol Pathol 1993; 58: 105–13
   PubMed Web of Science ®Google Scholar
• Polendo R, Lowe G N, McDougall S, Hahn T J. Mechanism of prostaglandin regulation proteoglycan synthesis in rat chondrocytic cells. (Abstract) J Bone Miner Res 1994; 9: S187
   Google Scholar
• Harada S, Duong L T, Adam M, et al. Expression of prostaglandin E2 receptors (EP1, EP2, EP3) in bone cells. (Abstract) J Bone Miner Res 1994; 9: S358
   Google Scholar
• Suda M, Tanaka K, Fukushima M, et al. Prostaglandin E2 (PGE2) receptor subtype mRNA in osteoblastic cell line. (Abstract) J Bone Miner Res 1994; 9: S356
   Google Scholar
• Boskey A L, Stiner D, Doty S B, Binderman I. Prostaglandins do not alter cartilage calcification in a differentiating chick limb-bud mesenchymal cell system. (Abstract) J Bone Miner Res 1994; 9: S376
   Google Scholar
• Velasquez F, Morales M, Sierra C, Socias F, Ito J. The prostaglandin E1 shortens mineralization lag time in cat's palatine bone disjunction. Histomorphometric study. (Abstract) J Bone Miner Res 1994; 9: S349
   Google Scholar
• Warren J B, Wilson A J, Loi R K, Coughlan M L. Opposing roles of cyclic AMP in the vascular control of edema formation. FASEBJ 1993; 7: 1394–1400
   PubMed Web of Science ®Google Scholar
• Norrdin R W, Shih M S. Systemic effects of prostaglandin E2 on vertebral trabecular remodeling in beagles used in a healing study. Calcif Tissue Int 1988; 42: 363–8
   PubMed Web of Science ®Google Scholar
• Keller J, Klamer A, Bak B, Suder P. Effects of local prostaglandin E2 on fracture callus in rabbits. Acta Orthop Scand 1993; 64: 59–63
   PubMed Web of Science ®Google Scholar